Compare InMode Ltd (INMD) vs TG Therapeutics Inc (TGTX) Price & Performance

InMode (INMD) trades at $14.08, up 0.5% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong profitability with 76.5% gross margins and 20.7% net income margin, though Q1 2026 earnings missed expectations. Recent developments include the launch of Morpheus8 Cool technology and an unsolicited acquisition offer from Steel Partners at $16.75 per share in July 2026.

Investment outlook is cautiously optimistic with attractive valuation metrics (P/E 11.6, EV/EBITDA 4.5) offset by near-term revenue stagnation. Key risks include US platform sales decline and management capital allocation concerns. Analyst consensus leans neutral with 45% buy ratings and 55% hold, suggesting potential upside if the acquisition materializes or international growth accelerates.

TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.

The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.